Journal
MOLECULAR METABOLISM
Volume 63, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.molmet.2022.101533
Keywords
Obesity; Pharmacology; Triagonist; Glucagon; GLP-1; GIP
Categories
Ask authors/readers for more resources
This study introduces empirically optimized unimolecular peptide triagonists, which effectively reduce body weight and enhance energy expenditure in DIO mice, outperforming GLP-1R mono-agonists and GLP-1R/GIPR co-agonists. The data suggest that unimolecular poly-pharmacology is an effective means to target obesity and implicate GcgR activation as a differentiating factor in incretin receptor agonists.
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (Gcg) receptors (i.e. triagonism), combines the anorectic and insulinotropic activities of GLP-1 and GIP with the energy expenditure effect of glucagon. While the efficacy of triagonism in preclinical models is known, the relative contribution of GcgR activation remains unassessed. This work aims to addresses that central question. Methods: Herein, we detail the design of unimolecular peptide triagonists with an empirically optimized receptor potency ratio. These optimized peptide triagonists employ a protraction strategy permitting once-weekly human dosing. Additionally, we assess the effects of these peptides on weight-reduction, food intake, glucose control, and energy expenditure in an established DIO mouse model compared to clinically relevant GLP1R agonists (e.g. semaglutide) and dual GLP-1R/GIPR agonists (e.g. tirzepatide). Results: Optimized triagonists normalize body weight in DIO mice and enhance energy expenditure in a manner superior to that of GLP-1R mono-agonists and GLP-1R/GIPR co-agonists. Conclusions: These pre-clinical data suggest unimolecular poly-pharmacology as an effective means to target multiple mechanisms contributing to obesity and further implicate GcgR activation as the differentiating factor between incretin receptor mono- or dual-agonists and triagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available